Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy?

[21] Morrow M(2017)Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of american society of breast surgeons members Ann Surg Oncol. 24 1565-812

[22] Simons JM(2021)Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA Study Cancers (Basel). 13 804-2629

[23] Koppert LB(2021)Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up Eur J Surg Oncol. 47 2621-4801

[24] Luiten EJT(2021)Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer Ann Surg Oncol. 28 4795-1855

[25] Boughey JC(2020)Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer Ann Surg Oncol. 27 1851-1311

[26] Suman VJ(2021)Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy: a rare event JAMA Oncol. 7 1307-3016

[27] Mittendorf EA(2018)Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy Eur J Surg Oncol. 44 3011-3157

[28] Kuehn T(2017)Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges Ann Surg Oncol. 24 3150-2159

[29] Bauerfeind I(2018)Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis Ann Surg Oncol. 25 2147-628

[30] Fehm T(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med. 376 617-3771

[21] Morrow M(2017)Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of american society of breast surgeons members Ann Surg Oncol. 24 1565-812

[22] Simons JM(2021)Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA Study Cancers (Basel). 13 804-2629

[23] Koppert LB(2021)Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up Eur J Surg Oncol. 47 2621-4801

[24] Luiten EJT(2021)Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer Ann Surg Oncol. 28 4795-1855

[25] Boughey JC(2020)Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer Ann Surg Oncol. 27 1851-1311

[26] Suman VJ(2021)Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy: a rare event JAMA Oncol. 7 1307-3016

[27] Mittendorf EA(2018)Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy Eur J Surg Oncol. 44 3011-3157

[28] Kuehn T(2017)Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges Ann Surg Oncol. 24 3150-2159

[29] Bauerfeind I(2018)Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis Ann Surg Oncol. 25 2147-628

[30] Fehm T(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med. 376 617-3771